Fulderm

Fulderm International is a UK-based dermatology-focused healthcare company within the Fulhold group that develops and commercializes products based on CarboHydrate Derived Fulvic Acid (CHD-FA). The company appears to be focused primarily on topical skin applications, including a drug-development program in atopic dermatitis and a marketed EU medical device product, Reczema, for irritated skin and mild eczema. Public information indicates that the broader group has engaged the FDA through a pre-IND process and has sponsored a Phase 2a South African study of topical CHD-FA in mild-to-moderate atopic dermatitis. Fulderm also appears tied to commercialization entities such as Fulderm Sweden AB, which is described as the EU market authorization holder for Reczema. Overall, Fulderm is best characterized as a small, private, specialty dermatology company built around a proprietary fulvic-acid platform.